AVAI (Avai Bio) 3-Year EBITDA Growth Rate: -38.70% (As of Dec. 2025)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.18
! 3 Warning Signs
View Full Analysis

What is Avai Bio 3-Year EBITDA Growth Rate?

Avai Bio AVAI +3.24% 24 3-Year EBITDA Growth Rate is -38.70% as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,082 Software companies, Avai Bio ranks worse than 93.28% on this metric.

Avai Bio's EBITDA per Share for the three months ended in Dec. 2025 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was -38.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -50.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avai Bio was -38.70% per year. The lowest was -100.00% per year. And the median was -41.45% per year.

Avai Bio  (OTCPK:AVAI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Avai Bio 3-Year EBITDA Growth Rate Related Terms

AVAI vs IPM, RCT, LPSN: 3-Year EBITDA Growth Rate Comparison

For the Software - Application subindustry, Avai Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avai Bio 3-Year EBITDA Growth Rate vs Software Industry

For the Software industry and Technology sector, Avai Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Avai Bio's 3-Year EBITDA Growth Rate falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -38.70% mean?
Avai Bio (AVAI) has a 3-Year EBITDA Growth Rate of -38.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #1942 out of 2082 companies in the Software industry, placing it in the top 93.3%.
Is Avai Bio's 3-Year EBITDA Growth Rate too high?
Avai Bio's current 3-Year EBITDA Growth Rate is -38.70%. Based on the distribution chart, Avai Bio ranks #1942 out of 2082 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's 3-Year EBITDA Growth Rate compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #1942 out of 2082 companies for 3-Year EBITDA Growth Rate. This places Avai Bio in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 12.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Software company?
The median 3-Year EBITDA Growth Rate among Software companies is 12.30, based on 2,082 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avai Bio and its competitors. For the Software industry, the median 3-Year EBITDA Growth Rate is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current 3-Year EBITDA Growth Rate is -38.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current 3-Year EBITDA Growth Rate of -38.70%. The current 3-Year EBITDA Growth Rate is -38.70%. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Avai Bio (AVAI), the current 3-Year EBITDA Growth Rate is -38.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price